FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Entera Bio's Free Cash Flow for the
three
months ended in Dec. 2024 was $-1.47 Mil. Entera Bio's Revenue for the
three
months ended in Dec. 2024 was $0.08 Mil. Therefore, Entera Bio's FCF Margin % for the quarter that ended in Dec. 2024 was -1,789.02%.
The historical rank and industry rank for Entera Bio's FCF Margin % or its related term are showing as below:
ENTX'
s FCF Margin % Range Over the Past 10 Years
Min: -9362.69 Med: -3337.68 Max: -1590.19
Current: -3766.85
During the past 10 years, the highest FCF Margin % of Entera Bio was -1590.19%. The lowest was -9362.69%. And the median was -3337.68%.
ENTX's FCF Margin % is ranked worse than 86.9% of 1008
companies
in the Biotechnology industry
Industry Median: -129.705
vs ENTX: -3766.85
Entera Bio FCF Margin % Historical Data
The historical data trend for Entera Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entera Bio's FCF Margin %
For the Biotechnology subindustry, Entera Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Entera Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio FCF Margin % Related Terms
Thank you for viewing the detailed overview of Entera Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 